Wren (www.wrentherapeutics.com) is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden), focused on drug discovery and development for protein misfolding diseases. Wren is advancing an entirely novel approach to address this class of diseases, based on more than a decade of research from its scientific founders focused on the chemical kinetics of the protein misfolding process. These advances make it possible to map, and selectively modulate, the complex and non-linear chemical kinetic networks associated with misfolding proteins and disease. Wren's predictive, quantitative platform is built on concepts from the physical sciences and is a fundamental shift from the descriptive, qualitative methods of traditional biology, which have failed to successfully address these complex systems. Wren is using its unique approach to develop a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases.
Founded date: 2016